# Brief Report: Ivonescimab Combined With Etoposide Plus Carboplatin as First-Line Treatment for Extensive-Stage SCLC: Results of a Phase 1b Clinical Trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/brief-report-ivonescimab-combined-with-etoposide-plus-carboplatin-as-first-line/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Zhiwei Chen,Lin Wu,Qiming Wang,Yan Yu,Xianling Liu,Rui Ma,Tao Li,Y. Li,Xia Song,Li Lin,Zhao Wei,Qiaoyun Wang,Xiao‐Quan Xu,Shun Lü |
| Citations | 18 |
| DOI | 10.1016/j.jtho.2024.10.013 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4403827568 |
| PMID | 39490738 |
| Type | article |
| Year | 2024 |

## Paper authors

- [Y. Li](https://scholariq.org/researchers/y-li/)

## Paper journal

- [Journal of Thoracic Oncology](https://scholariq.org/journals/journal-of-thoracic-oncology/)

## Paper primary topic

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Paper topics

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.